TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02990351

Intervention type: PROCEDURE
Intervention: loco regional therapies for HCC
Description: 29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
Study: NCT05241600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Childbirth and Parenting
Description: MBCP is an adaptation of MBSR that incorporates both standard mindfulness practices (body scan, sitting meditation, mindful movement) and preparation for mindful birthing and parenting an infant. The class is taught by experienced midwives or social workers who have completed MBCP training requirements, which include ongoing cultivation of a personal mindfulness practice as well as education and supervision specific to the MBCP program. See Bardacke (2012) for further description of the MBCP curriculum.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Mindfulness-Based Childbirth Class
Description: Other childbirth preparation classes available either in-person in the local community or online that do not involve formal mindfulness training will serve as the comparator condition.
Study: NCT03509870

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: mesenchymal stromal cells
Description: mesenchymal stromal cells in a collagen scaffold
Study: NCT02386930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behvarioal lifestyle modification
Description: A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
Study: NCT02026336

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: electronic nose
Description: Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile.
Study: NCT03536949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 ophthalmic solution, 0.1%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: Vehicle placebo ophthalmic solution
Study: NCT00560287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers
Description: A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers
Description: A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
Study: NCT02651805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Insufflation-Exsufflation
Description: Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Insufflation-Exsufflation
Description: Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
Study: NCT01472757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VR506
Description: VR506 inhalation powder delivered via a new dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered via a new dry powder inhaler
Study: NCT03757637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NLSCP
Description: Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICT supported HAP
Description: Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
Study: NCT03195023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
Study: NCT03444051

Intervention type: PROCEDURE
Intervention: EUS-FNB with 20-gauge Procore® needle
Description: Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle

Intervention type: PROCEDURE
Intervention: EUS-FNB with 22-gauge Acquire® needle
Description: Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
Study: NCT01902758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan and theophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for comparison group
Study: NCT02308813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking and functionality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Braking and functionality
Study: NCT00948506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1% topical cidofovir
Description: 1% topical cidofovir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3% topical cidofovir
Description: 3% topical cidofovir
Study: NCT02515656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLYGYNAX®
Study: NCT00948506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical placebo
Study: NCT02515656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GYNODAKTARIN®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03982875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfred SmartBag
Description: The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
Study: NCT04192058

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Description: For sham treatment we will use the same assembly as the active ETCC. However, we will apply the current for 30s at the start of the stimulation session and 30s at the end of the session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) it is a therapeutic method that modulates membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it. The position of the electrodes will be performed based on a 10-20 system according to the international EEG unit system, with the location of the electrodes at C3 and F3, respectively. The anode will be positioned over the left hemisphere at C3 while the cathode will be positioned over the contralateral hemisphere F3. During active stimulation a 2.0mA current released by a 35 cm2 electrode will be used for 20 min.
Study: NCT01458717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Description: * Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* 4 weeks rest, re-evaluation for resectability~* operation~* start maintenance chemotherapy within 4\~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upfront surgery
Description: * Operation at time of diagnosis~* Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~* start maintenance chemotherapy within 4\~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle
Study: NCT02679833

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Toothpaste not containing the vitamin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin
Description: Toothpaste containing100 µg cyanocobalamin/g.
Study: NCT03153267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 MG Oral Tablet bid, 7 days
Description: Patients will receive doxycycline for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline 100 MG Oral Tablet bid, 14 days
Description: Patients will receive doxycycline for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Controls without a history of lyme disease.
Description: No intervention.
Study: NCT00659698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)
Description: artificial pancreas
Study: NCT06133946

Intervention type: GENETIC
Intervention: Genetic screening test (Deafness gene variant detection array kit)
Description: Infant participants were screened for fifteen variants in four genes (i.e., GJB2, SLC26A4, MT-RNR1 and GJB3).
Study: NCT01485445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (200mcg unit strength)
Description: inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (200mcg unit strength)
Description: inhalation powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/Vilanterol (200/25mcg unit strength)
Description: inhalation powder
Study: NCT02957045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough pressure measurement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pcough
Study: NCT00951834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-Gallate
Description: Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~* Months 1-3: 200 mg EGCG/die (200-0-0 mg)~* Months 4-6: 400 mg EGCG/die (200-0-200 mg)~* Months 7-9: 600 mg EGCG/die (400-0-200 mg)~* Months 10-18: 800 mg EGCG/die (400-0-400 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04605432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-FFI
Description: Patients with risk factor : on the day before the colonoscopy at 20:00- 21:00 hours, 60gPEG-4000 was mixed with 1L water; 4-6 h before colonoscopy, 120gPEG-4000 was mixed with 2L water.~Patient without risk factor: 4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by experienced researcher.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-nonFFI
Description: All patients on the day of the colonoscopy:4-6 hours before colonoscopy, 120gPEG-4000 was mixed with 3L water.~Education completed by ward nurse.
Study: NCT02329223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study: NCT04854278

Intervention type: OTHER
Intervention: Massive Open Online Course (MOOC)
Description: Combination of knowledge training with video scenarios and game-based learning provided to endovascular team members: surgeons, nurses and anesthetists
Study: NCT01779167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \& 27)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \& 28). Lenalidomide will be initiated at a starting dose of 5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
Study: NCT03059706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RegenoGel-OSP™
Description: intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intra-articular injection of saline after arthroscopic surgery
Study: NCT01730651

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: IMRT boost of gross LNs~1. Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~2. Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)
Study: NCT04101032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eBEfree
Description: Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
Study: NCT02307084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging of the long saphenous vein
Description: Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
Study: NCT03801824

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Therapy
Description: Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
Study: NCT02306213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch 6% 130/0.4
Description: Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard volume therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard volume therapy
Study: NCT02782598

Intervention type: DEVICE
Intervention: CRT+NAVH
Description: Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
Study: NCT02217241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handoff Workshop
Study: NCT03067610

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
Study: NCT02591914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista™
Description: Anti-PDGF-B pegylated aptamer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis®
Description: Anti-VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin®
Description: Anti-VEGF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea®
Description: Anti-VEGF
Study: NCT01319864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor Dose Escalation
Description: Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy.
Study: NCT04208542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Ultrasound guided Erector spinae block (ESP) will perform.
Study: NCT00420563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYCLOPHOSPHAMIDE
Description: 50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEGESTROL
Description: 320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
Study: NCT02004132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axiron
Description: Solution administered topically using pump and applicator